Neurizon inks $1.5M loan against R&D Tax Rebate
Neurizon Therapeutics (ASX:NUZ) retreated in intra-day trade on Wednesday after inking a non-dilutive loan agreement for $1.5 million to fund its current and future operations seeking to treat Huntington’s with its flagship drug NUZ-001.The funds in question are secured against it...
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
DGL | Ann: DGL - Appointment of Chief Executive Officer | 01/07/25 | 0 | 86 | |||
|
|||||||
DGL | Ann: Ongoing Disclosure Notice - Gordon MacLeod | 02/05/25 | 0 | 87 | |||
|
|||||||
DGL | Ann: DGL - 2025 Harvest Announcement | 28/04/25 | 0 | 111 | |||
|
|||||||
DGL | Ann: DGL-Case sales and Profit Guidance Update -US tariff impact | 28/04/25 | 0 | 92 | |||
|
|||||||
DGL | Ann: DGL - US Tariff Announcement | 03/04/25 | 0 | 103 | |||
|
|||||||
DGL | Ann: DGL - Director Independence Outcome - D McKay | 10/03/25 | 0 | 113 | |||
|
|||||||
DGL | Ann: Director Independence Review - D McKay | 10/03/25 | 0 | 128 | |||
|
|||||||
DGL | Ann: DGL - Interim Results to 31 December 2024 | 28/02/25 | 0 | 171 | |||
|
See All Discussions